Biotech News

Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026

Personalis (PSNL)PersonalisConference / presentation

Late-breaking oral presentation highlights the role of ultrasensitive ctDNA in drug development; first data from prospective B-STRONGER-1 study in early-stage triple-negative breast cancer FREMONT, Calif. --(BUSINESS WIRE)--Oct. 21, 2026-- Personalis, Inc.

Related news

Personalis

Precision-Oncology Genomics Personalis develops genomic tests for cancer detection, monitoring and therapy development. Its platform uses highly sensitive sequencing and tumor-informed analysis to identify minimal residual disease. NeXT Personal NeXT Personal is a personalized circulating-tumor-DNA test designed to detect and track...

Recent company news

Stock data

Close
14.72 USD
Market cap
1.17B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States